InsidersTradesSigma
Total declarations
Companies
▲ Purchases (31 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
31
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+46.8%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by GOEDDEL DAVID V, Director. Officer active across 2 companies, notably Tenaya Therapeutics, Inc.. In total, 34 reports have been recorded. Breakdown: 31 buys · 0 sell. Total volume traded: €79.8m. Activity tracked since 3 August 2021. The latest transaction was disclosed on 5 March 2025 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations34 total
35,714,284 shares@ US$0.7038.6% of flowCommon StockSEC:0000950170-25-035788:0
Ideal exit: 30 Nov 2025 (T+270)
134,180 sharesCommon StockSEC:0000950142-24-000999:0
2,222,222 shares@ US$4.5015.2% of flowCommon StockSEC:0000950170-24-015219:0
Ideal exit: 8 Nov 2024 (T+270)
2,720 shares@ US$0.70540.0% of flowCommon StockSEC:0000950170-23-064842:0
Ideal exit: 11 Aug 2024 (T+270)
6,779 shares@ US$2.59560.0% of flowCommon StockSEC:0000899243-23-008389:0
Ideal exit: 5 Dec 2023 (T+270)
1,500,000 shares@ US$2.606.0% of flowCommon StockSEC:0000899243-23-004580:0
Ideal exit: 5 Nov 2023 (T+270)
7,542 shares@ US$4.99960.2% of flowCommon StockSEC:0000899243-23-003129:0
Ideal exit: 27 Oct 2023 (T+270)
9,900 shares@ US$4.99940.2% of flowCommon StockSEC:0000899243-23-002621:0
Ideal exit: 20 Oct 2023 (T+270)
69,739 shares@ US$2.49790.3% of flowCommon StockSEC:0000899243-23-002377:0
Ideal exit: 16 Oct 2023 (T+270)
37,639 shares@ US$4.99760.9% of flowCommon StockSEC:0000899243-23-002371:0
Ideal exit: 16 Oct 2023 (T+270)
49,463 shares@ US$2.49470.2% of flowCommon StockSEC:0000899243-23-002158:0
Ideal exit: 14 Oct 2023 (T+270)
5,378 shares@ US$4.94660.1% of flowCommon StockSEC:0000899243-23-001851:0
Ideal exit: 9 Oct 2023 (T+270)
100,070 shares@ US$4.84182.4% of flowCommon StockSEC:0000899243-23-001690:0
Ideal exit: 7 Oct 2023 (T+270)
300 shares@ US$4.97670.0% of flowCommon StockSEC:0000899243-22-038460:0
Ideal exit: 8 Sept 2023 (T+270)
35,997 shares@ US$4.99880.9% of flowCommon StockSEC:0000899243-22-036908:0
Ideal exit: 18 Aug 2023 (T+270)
9,615,384 shares@ US$2.6039.7% of flowCommon StockSEC:0000899243-22-036907:0
Ideal exit: 18 Aug 2023 (T+270)
104,090 shares@ US$4.98712.8% of flowCommon StockSEC:0000899243-22-035273:0
Ideal exit: 31 Jul 2023 (T+270)
76,877 shares@ US$4.86022.0% of flowCommon StockSEC:0000899243-22-034564:0
Ideal exit: 24 Jul 2023 (T+270)
51,046 shares@ US$4.74841.3% of flowCommon StockSEC:0000899243-22-034355:0
Ideal exit: 22 Jul 2023 (T+270)
50,000 shares@ US$3.18280.9% of flowCommon StockSEC:0000899243-22-033838:0
Ideal exit: 14 Jul 2023 (T+270)
951,684 shares@ US$13.5072.4% of flowCommon StockSEC:0000899243-22-022210:0
Ideal exit: 6 Mar 2023 (T+270)
33,071 shares@ US$13.03332.4% of flowCommon StockSEC:0000899243-22-021211:0
Ideal exit: 27 Feb 2023 (T+270)
59,766 shares@ US$13.46584.5% of flowCommon StockSEC:0000899243-22-020683:0
Ideal exit: 25 Feb 2023 (T+270)
19,534 shares@ US$13.49351.5% of flowCommon StockSEC:0000899243-22-020199:0
Ideal exit: 20 Feb 2023 (T+270)
17,240 shares@ US$13.3681.3% of flowCommon StockSEC:0000899243-22-019685:0
Ideal exit: 18 Feb 2023 (T+270)
25 of 34 declarations
About GOEDDEL DAVID V
David V. Goeddel is a Board Member at Tenaya Therapeutics, Inc. and NGM Biopharmaceuticals Inc. In this role, he participates in the governance of the companies and strategic decision-making. David V. Goeddel brings valuable expertise in the biotechnology field, supporting innovation and the development of new treatments. His commitment to excellence and corporate responsibility is an asset to the boards.
